Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 6/20 | 0.38 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | CTSS | P25774 | 4/20 | 0.38 |
| ▸ | CTSK | P43235 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4179051 | 0.84 | PPARA (0.40) | TRPA1PPARAPPARGCTSSCTSK | |
| SCHEMBL4172572 | 0.81 | S1PR3 (0.41) | TRPA1PPARAPPARGCTSSCTSK | |
| SCHEMBL4181570 | 0.80 | TSHR (0.39) | TRPA1CTSSCTSKATMATR | |
| SCHEMBL12070284 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM | |
| SCHEMBL7087412 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM | |
| SCHEMBL335777 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM | |
| SCHEMBL6166 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM | |
| SCHEMBL13363641 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM | |
| SCHEMBL767076 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM | |
| SCHEMBL144832 | 0.79 | CTSK (0.51) | PPARAPPARGCTSSCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | DAIICHI SANKYO COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1942109-A1 | TAXANE COMPOUND WITH AZETIDINE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186868-A1 | Taxane Compound Having Azetidine Ring Structure | ABCC1, AZI2, TPD52L2 | TRPA1 3951/4885PPARA 2846/4885PPARG 3882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.